VMS Rehab Systems, Inc. (VRSYF) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
VMS Rehab Systems, Inc. (VRSYF) trades at $0.0001. VMS Rehab Systems, Inc. operates in the healthcare sector, focusing on generic drugs and home healthcare products. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for VRSYF: VRSYF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates VRSYF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
VRSYF: 1/3 scored disciplines lean bearish. Dominant signal: Izzy Englander bullish.
How is this calculated? →VMS Rehab Systems, Inc. (VRSYF) Healthcare & Pipeline Overview
VMS Rehab Systems, Inc., based in Canada, focuses on generic drug development and home healthcare, specifically orthopedic wedge seat cushions. With a high profit margin of 64.8% but negative gross margin, the company caters to a niche market within the broader healthcare sector, facing competition from larger medical device and pharmaceutical companies.
What Is the Investment Thesis for VRSYF?
VMS Rehab Systems, Inc. presents a unique investment profile due to its dual focus on generic drug development and home healthcare products. The company's high profit margin of 64.8% suggests potential profitability, although the negative gross margin of -14.6% warrants further investigation into cost structures. Key value drivers include successful development and regulatory approval of generic tadalafil products and expansion of its orthopedic cushion sales through existing and new retail channels. Upcoming catalysts include potential partnerships or acquisitions to broaden its product portfolio. However, the company's small market capitalization and OTC listing introduce liquidity and regulatory risks. Investors should carefully assess the company's ability to manage costs, navigate the competitive landscape, and achieve sustainable growth.
Based on FMP financials and quantitative analysis
VRSYF Key Highlights
Market Cap of $0.00B indicates a micro-cap company with limited liquidity and higher volatility.
- Profit Margin of 64.8% suggests strong profitability on sales, but needs to be evaluated in the context of its negative gross margin.
- Gross Margin of -14.6% indicates that the cost of goods sold exceeds revenue, raising concerns about pricing strategy and operational efficiency.
- Beta of 9.21 indicates extremely high volatility compared to the overall market, suggesting a high-risk investment.
- The company focuses on generic drug development and home healthcare products, specifically orthopedic wedge seat cushions.
Who Are VRSYF's Competitors?
VRSYF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CNVIF Conavi Medical Corp. | $0.13 | -1.19% | $11.4M | 66 |
| VPTDF VentriPoint Diagnostics Ltd. | $0.07 | -4.02% | $13.8M | 62 |
| LHDX Lucira Health, Inc. | $0.45 | +0.00% | $18.4M | 64 |
| PLSM PLSM | $2.96 | -1.66% | $19.3M | 60 |
| PYNKF Perimeter Medical Imaging AI, Inc. | $0.27 | -1.08% | $24.6M | 73 |
| RDGL Vivos Inc. | $0.05 | -5.33% | $26.5M | 61 |
| NVYTF Novacyt S.A. | $0.48 | -0.00% | $34.8M | 61 |
| DNAY Codex DNA, Inc. | $1.30 | +8.33% | $38.3M | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are VRSYF's Key Strengths?
Specialized product offerings (orthopedic cushions).
- High profit margin (64.8%).
- Established presence in Canadian home healthcare retail networks.
- Potential for cost advantages in generic drug development.
What Are VRSYF's Weaknesses?
Negative gross margin (-14.6%).
- Small market capitalization ($0.00B).
- Limited geographic reach (primarily Canada).
- OTC listing (lower liquidity and regulatory oversight).
What Could Drive VRSYF Stock Higher?
Potential regulatory approval of generic tadalafil products.
- Expansion of orthopedic cushion sales through existing retail channels.
- Strategic partnerships with other healthcare companies.
- Product innovation and development of new healthcare solutions.
What Are the Key Risks for VRSYF?
Negative return on equity (-20.1%) — the business is not currently generating profit on shareholder capital.
- Competition from larger medical device and pharmaceutical companies.
- Regulatory challenges in generic drug approval.
- Economic downturn affecting consumer spending on healthcare products.
- Changes in healthcare policies and reimbursement rates.
- Limited liquidity due to OTC listing.
What Are the Growth Opportunities for VRSYF?
- Expansion of Orthopedic Cushion Sales: VMS Rehab Systems can expand its sales of orthopedic wedge seat cushions by targeting new geographic markets and retail channels. The global market for orthopedic products is substantial, and the company can leverage its existing product line to capture a larger share. By focusing on online sales and partnerships with healthcare providers, VMS Rehab Systems can reach a broader customer base. Timeline: Within the next 2-3 years.
- Generic Drug Development: The company can pursue the development and commercialization of additional generic drugs. The generic drug market offers significant opportunities for companies that can successfully navigate the regulatory approval process and bring cost-effective alternatives to market. VMS Rehab Systems can focus on niche therapeutic areas where it has a competitive advantage. Timeline: Ongoing, with potential product launches in the next 3-5 years.
- Strategic Partnerships: VMS Rehab Systems can form strategic partnerships with other healthcare companies to expand its product portfolio and market reach. These partnerships can provide access to new technologies, distribution channels, and customer segments. By collaborating with complementary businesses, VMS Rehab Systems can accelerate its growth and enhance its competitive position. Timeline: Ongoing.
- Product Innovation: The company can invest in research and development to create new and innovative healthcare products. By focusing on unmet medical needs and developing differentiated products, VMS Rehab Systems can attract new customers and generate higher margins. This includes exploring new materials and designs for its orthopedic cushions and developing novel drug delivery systems for its generic drugs. Timeline: Ongoing, with potential product launches in the next 3-5 years.
- Acquisition Opportunities: VMS Rehab Systems can pursue strategic acquisitions to expand its product portfolio and market presence. By acquiring complementary businesses, the company can gain access to new technologies, distribution channels, and customer segments. This can accelerate its growth and enhance its competitive position in the healthcare market. Timeline: Opportunistic, depending on market conditions and available targets.
What Are VRSYF's Competitive Advantages?
- Specialized product offerings in orthopedic cushions.
- Established relationships with home healthcare retail networks in Canada.
- Potential for cost advantages in generic drug development.
- Focus on niche market segments.
What Does VRSYF Do?
Founded in 1998 in Ottawa, Canada, VMS Rehab Systems, Inc. operates within the healthcare sector, focusing on generic drug development and the home healthcare market. The company's initial focus was on developing and testing generic tadalafil products, aiming to provide cost-effective alternatives to established medications. Additionally, VMS Rehab Systems manufactures and distributes orthopedic wedge seat cushions designed to alleviate discomfort and pain associated with lower body medical conditions such as pilonidal disease, piles, and hemorrhoids. These cushions are primarily sold through home healthcare retail networks in Canada. The company's business model combines pharmaceutical development with the manufacturing and distribution of specialized medical devices. While the generic drug segment aims to capture a share of the pharmaceutical market by offering affordable alternatives, the orthopedic cushion business targets a specific niche within the broader home healthcare market. VMS Rehab Systems' geographic focus is primarily within Canada, where it has established relationships with home healthcare retailers. The company faces competition from both generic drug manufacturers and producers of orthopedic and medical devices. Its success depends on navigating the regulatory landscape for generic drugs, maintaining its distribution network, and effectively marketing its specialized products.
What Products and Services Does VRSYF Offer?
- Develops and tests generic tadalafil products.
- Sells orthopedic wedge seat cushions.
- Targets home healthcare retail networks in Canada.
- Addresses discomfort and pain caused by lower body medical issues.
- Offers products for pilonidal disease, piles disease, and hemorrhoids.
- Operates in the healthcare sector.
How Does VRSYF Make Money?
- Develops generic drugs for commercialization.
- Manufactures and distributes orthopedic wedge seat cushions.
- Sells products through home healthcare retail networks.
- Focuses on the Canadian market.
What Industry Does VRSYF Operate In?
VMS Rehab Systems, Inc. operates in the healthcare sector, which is experiencing growth driven by an aging population and increasing demand for medical devices and generic drugs. The generic drug market is also expanding as patents expire on branded pharmaceuticals. VMS Rehab Systems competes with larger medical device companies and generic drug manufacturers. Competitors include companies like BLFE, BNYN, EMED, EMYSF, and EVARF. The company's success depends on its ability to innovate, obtain regulatory approvals, and effectively market its products in a competitive landscape.
Who Are VRSYF's Key Customers?
- Individuals suffering from pilonidal disease.
- Individuals suffering from piles disease.
- Individuals suffering from hemorrhoids.
- Home healthcare retail networks in Canada.
Company Profile
VMS Rehab Systems, Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Ottawa, CA. The company is led by CEO Michael S. Wexler. VRSYF has traded publicly since 2015.
Key Financial Metrics
Return on equity for VMS Rehab Systems, Inc. stands at -20.1%, a gauge of how efficiently it converts shareholder capital into profit. VRSYF trades at a trailing price-to-earnings ratio of 0.00, below the Healthcare sector average of ~23x. Its free cash flow yield is -0.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.05 means current liabilities exceed short-term assets, a liquidity point worth watching.
VRSYF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Specialized product offerings (orthopedic cushions).
- High profit margin (64.8%).
- Established presence in Canadian home healthcare retail networks.
- Potential for cost advantages in generic drug development.
Bear Case
- Negative gross margin (-14.6%).
- Small market capitalization ($0.00B).
- Limited geographic reach (primarily Canada).
- OTC listing (lower liquidity and regulatory oversight).
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
VRSYF Latest News
No recent news available for VRSYF.
VRSYF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for VRSYF.
Price Targets
Wall Street price target analysis for VRSYF.
VRSYF MoonshotScore
What does this score mean?
The MoonshotScore rates VRSYF 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Michael S. Wexler
CEO
Michael S. Wexler serves as the CEO of VMS Rehab Systems, Inc. His background includes experience in the healthcare and pharmaceutical industries. He has held various leadership positions in companies focused on generic drug development and medical device manufacturing. Wexler's expertise lies in strategic planning, product development, and market expansion. He has a strong understanding of the regulatory landscape and the challenges of bringing new healthcare products to market. His educational background includes a degree in business administration and advanced studies in pharmaceutical sciences.
Track Record: Under Michael Wexler's leadership, VMS Rehab Systems, Inc. has focused on developing generic tadalafil products and expanding its orthopedic cushion business. Key achievements include establishing relationships with home healthcare retail networks in Canada and navigating the regulatory approval process for generic drugs. Strategic decisions have included investing in research and development to create new and innovative healthcare products. Company milestones include the launch of new orthopedic cushion designs and the expansion of its product portfolio.
VRSYF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that VMS Rehab Systems, Inc. may not meet the minimum financial standards or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may be subject to less regulatory oversight compared to companies listed on major exchanges like the NYSE or NASDAQ. This tier signifies a higher level of risk for investors due to the potential for limited information and liquidity.
- OTC Tier: OTC Other
- Limited liquidity due to low trading volume.
- Higher price volatility compared to exchange-listed stocks.
- Potential for limited financial disclosure and transparency.
- Risk of delisting or trading suspension.
- Greater susceptibility to market manipulation.
- Verify the company's financial statements and SEC filings.
- Assess the company's management team and their experience.
- Evaluate the company's business model and competitive landscape.
- Review the company's legal and regulatory compliance.
- Analyze the company's cash flow and debt levels.
- Check for any pending lawsuits or investigations.
- Monitor news and press releases for any material developments.
- Company has been in operation since 1998.
- Focus on developing generic drugs and home healthcare products.
- Established relationships with home healthcare retail networks in Canada.
- CEO with experience in the healthcare and pharmaceutical industries.
VRSYF Healthcare Stock FAQ
What does VMS Rehab Systems, Inc. do?
VMS Rehab Systems, Inc. operates in the healthcare sector, focusing on generic drug development and the manufacturing and distribution of orthopedic wedge seat cushions. The company develops generic tadalafil products, aiming to provide cost-effective alternatives to established medications. Additionally, it manufactures and sells orthopedic cushions designed to alleviate discomfort and pain associated with lower body medical conditions.
What do analysts say about VRSYF stock?
As of 2026-03-17, there is no available analyst coverage for VRSYF stock. Given its OTC listing and small market capitalization, the stock may not be widely followed by analysts. Investors should conduct their own due diligence and carefully evaluate the company's financial performance, growth prospects, and risk factors.
What are the main risks for VRSYF?
VMS Rehab Systems, Inc. faces several risks, including competition from larger medical device and pharmaceutical companies, regulatory challenges in generic drug approval, and economic downturns affecting consumer spending on healthcare products. The company's OTC listing also presents liquidity risks and potential for limited financial disclosure. Additionally, changes in healthcare policies and reimbursement rates could impact the company's profitability. Investors should carefully assess these risks before investing in VRSYF stock.
What are the key factors to evaluate for VRSYF?
Evaluate VRSYF on fundamentals, analyst consensus, and risk factors. P/E: 0.0x vs the S&P 500's ~20-25x. VMS Rehab Systems, Inc. Not financial advice.
How frequently does VRSYF data refresh on this page?
VRSYF's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven VRSYF's recent stock price performance?
VMS Rehab Systems, Inc. (VRSYF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized product offerings (orthopedic cushions). See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider VRSYF overvalued or undervalued right now?
VMS Rehab Systems, Inc. (VRSYF) trades at 0.0x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research VRSYF before investing?
Before investing in VMS Rehab Systems, Inc. (VRSYF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is limited and may not be fully up-to-date.
- OTC stocks carry higher risks than exchange-listed stocks.
- Analyst coverage is limited for this company.